Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Phase 3 Active not recruiting 265 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).

Timeline

Start: 2023-07-20
Primary completion: 2026-05
Completion: 2026-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Jaktinib	Unknown	100 mg	Oral

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Summary

Timeline

Drugs

Indications